Exome Sequencing in the Diagnostic Pathway for Suspected Rare Genetic Diseases: Does the Order of Testing Affect its Cost-Effectiveness?

Koen Degeling, Toni Tagimacruz, Karen V. MacDonald, Trevor A. Seeger, Katharine Fooks, Viji Venkataramanan, Kym M. Boycott, Francois P. Bernier, Roberto Mendoza-Londono, Taila Hartley, Robin Z. Hayeems and Deborah A. Marshall ()
Additional contact information
Koen Degeling: The University of Melbourne
Toni Tagimacruz: University of Calgary
Karen V. MacDonald: University of Calgary
Trevor A. Seeger: University of Calgary
Katharine Fooks: The Hospital for Sick Children
Viji Venkataramanan: The Hospital for Sick Children
Kym M. Boycott: Children’s Hospital of Eastern Ontario Research Institute
Francois P. Bernier: University of Calgary
Roberto Mendoza-Londono: The Hospital for Sick Children
Taila Hartley: Children’s Hospital of Eastern Ontario Research Institute
Robin Z. Hayeems: The Hospital for Sick Children
Deborah A. Marshall: University of Calgary

Applied Health Economics and Health Policy, 2025, vol. 23, issue 3, No 8, 453-466

Abstract: Abstract Background Patients with suspected rare diseases often experience lengthy and uncertain diagnostic pathways. This study aimed to estimate the cost-effectiveness of exome sequencing (ES) in different positions in the diagnostic pathway for patients suspected of having a rare genetic disease. Methods Data collected retrospectively from 305 patients suspected of having a rare genetic disease (RGD), who received clinical-grade ES and participated in the Canadian multicentre Care4Rare-SOLVE study, informed a discrete event simulation of the diagnostic pathway. We distinguished between tests that can lead to the diagnosis of a specific RGD (‘indicator tests’) and more routine non-RGD diagnostic tests (‘non-indicator tests’). Five strategies were considered: no-ES, and ES as 1st, 2nd, 3rd, or 4th test (Tier 1, Tier 2, Tier 3, and Tier 4, respectively), where ES was the final test in the diagnostic pathway if included. Outcomes included the diagnostic yield, time-to-diagnosis, time on the diagnostic pathway, and test costs for each strategy. The cost-effectiveness analysis from a Canadian healthcare system perspective was conducted with diagnostic yield as the primary outcome of interest. Probabilistic analyses and expert-defined scenario analyses quantified uncertainty. Results Implementing ES increases the diagnostic yield by 16 percentage points from 20% with no-ES to 36%. Exome sequencing, as the first test (Tier 1), resulted in the shortest time to a diagnosis and the lowest testing cost. Mean testing costs per patient were CAD4347 (95% CI 3925, 4788) for no-ES, CAD2458 (95% CI 2406, 2512) for Tier 1, CAD3851 (95% CI 3684, 4021) for Tier 2, CAD5246 (95% CI 4956, 5551) for Tier 3 and CAD6422 (95% CI 5954, 6909) for Tier 4, with Tier 1 having the highest diagnostic yield at the lowest cost. The scenario analyses yielded results consistent with those of the base case. Conclusions Implementing ES to diagnose patients suspected of having a RGD can result in a higher diagnostic yield. Although a limitation of our study was that the yield for the non-ES indicator tests was estimated using expert opinion due to a lack of available data, the results underscore the value of ES as a first-line diagnostic test, offering reduced time to diagnosis and lower overall testing costs.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40258-024-00936-7 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:23:y:2025:i:3:d:10.1007_s40258-024-00936-7

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-024-00936-7

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().